Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer.
作者信息
Nielsen H J, Pappot H, Christensen I J, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J
机构信息
Department of Surgical Gastroenterology, Hvidovre Hospital, Denmark.
出版信息
BMJ. 1998 Mar 14;316(7134):829-30. doi: 10.1136/bmj.316.7134.829.
Abstract
摘要
相似文献
1
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer.血浆纤溶酶原激活物抑制剂-1浓度与结直肠癌患者生存率之间的关联。
BMJ. 1998 Mar 14;316(7134):829-30. doi: 10.1136/bmj.316.7134.829.
2
3
Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful.血浆纤溶酶原激活物抑制剂-1与结直肠癌生存率之间的关联。检测C反应蛋白浓度可能更有用。
BMJ. 1998 Sep 12;317(7160):750-1. doi: 10.1136/bmj.317.7160.750.
4
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.尿激酶型纤溶酶原激活剂与其1型抑制剂的复合物预示576例淋巴结阴性乳腺癌患者预后不良。
Cancer. 2004 Aug 1;101(3):486-94. doi: 10.1002/cncr.20374.
5
[New prognostic and predictive factors in advanced colorectal cancer].[晚期结直肠癌的新预后和预测因素]
Med Clin (Barc). 2006 Apr 15;126(14):541-8. doi: 10.1157/13087141.
6
Plasma Levels of Plasminogen Activator Inhibitor Type 1 and Vitronectin in Children With Cancer.癌症患儿血浆中1型纤溶酶原激活物抑制剂和玻连蛋白的水平
Clin Appl Thromb Hemost. 2016 Jan;22(1):28-33. doi: 10.1177/1076029614531450. Epub 2014 Apr 24.
7
Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.血浆纤溶酶原激活物抑制剂-1（PAI-1）水平与乳腺癌 - 与临床结局的关系。
Anticancer Res. 2014 Mar;34(3):1153-61.
8
Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer.结直肠癌患者诊断前血浆脂联素水平与生存率
Cancer Prev Res (Phila). 2015 Dec;8(12):1138-45. doi: 10.1158/1940-6207.CAPR-15-0175. Epub 2015 Sep 17.
9
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.尿激酶型纤溶酶原激活物系统和骨桥蛋白在接受放疗的非小细胞肺癌患者中的共同检测对预后的影响及其与大体肿瘤体积的相关性。
Strahlenther Onkol. 2018 Jun;194(6):539-551. doi: 10.1007/s00066-017-1255-1. Epub 2018 Jan 16.
10
Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Anticancer Res. 2000 Jan-Feb;20(1B):569-72.
引用本文的文献
1
Coculture of cancer cells with platelets increases their survival and metastasis by activating the TGFβ/Smad/PAI-1 and PI3K/AKT pathways.血小板与癌细胞共培养可通过激活 TGFβ/Smad/PAI-1 和 PI3K/AKT 通路来增加癌细胞的存活和转移。
Int J Biol Sci. 2023 Aug 15;19(13):4259-4277. doi: 10.7150/ijbs.85986. eCollection 2023.
2
Human α-defensin 6 (HD6) suppresses CRC proliferation and metastasis through abolished EGF/EGFR signaling pathway.人α-防御素 6（HD6）通过废除 EGF/EGFR 信号通路抑制 CRC 的增殖和转移。
Int J Med Sci. 2022 Jan 1;19(1):34-46. doi: 10.7150/ijms.64850. eCollection 2022.
3
Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.循环肿瘤细胞与高凝状态：转移性乳腺癌的致命关联。
Clin Transl Oncol. 2020 Jun;22(6):870-877. doi: 10.1007/s12094-019-02197-6. Epub 2019 Aug 31.
4
VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma.VHL状态调节肾细胞癌中的转化生长因子-β信号通路。
Oncotarget. 2018 Mar 27;9(23):16297-16310. doi: 10.18632/oncotarget.24631.
5
Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma.转化生长因子-β促进肾透明细胞癌的侵袭性和侵袭能力。
Oncotarget. 2016 Jun 14;7(24):35917-35931. doi: 10.18632/oncotarget.9177.
6
In vitro evaluation of anticancer properties of exopolysaccharides from Lactobacillus acidophilus in colon cancer cell lines.嗜酸乳杆菌胞外多糖对结肠癌细胞系抗癌特性的体外评估
In Vitro Cell Dev Biol Anim. 2016 Feb;52(2):163-73. doi: 10.1007/s11626-015-9970-3. Epub 2015 Dec 10.
7
Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures.基质金属蛋白酶-1组织抑制剂在结直肠癌肝转移中的表达与血管结构相关。
Mol Carcinog. 2016 Feb;55(2):193-208. doi: 10.1002/mc.22269. Epub 2015 Jan 15.
8
A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer.一种基于肿瘤相关胰蛋白酶抑制剂的新型判别评分法，用于准确诊断乳腺癌患者的转移情况。
Tumour Biol. 2014 Mar;35(3):2759-67. doi: 10.1007/s13277-013-1366-y. Epub 2013 Nov 13.
9
Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.纤溶酶原激活物抑制剂-1 与结直肠肿瘤的相关性。
Gut Liver. 2013 Sep;7(5):519-23. doi: 10.5009/gnl.2013.7.5.519. Epub 2013 Jun 11.
10
Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls.与健康对照组相比，结直肠肿瘤患者和病态肥胖患者的脂肪细胞因子浓度发生了变化。
BMC Cancer. 2012 Nov 23;12:545. doi: 10.1186/1471-2407-12-545.
本文引用的文献
1
2
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated.
Clin Chem. 1994 Jan;40(1):110-5.
3
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.卵巢癌患者血液和肿瘤液中的纤溶酶原激活剂及纤溶酶原激活剂抑制剂
Eur J Cancer. 1994;30A(9):1302-9. doi: 10.1016/0959-8049(94)90178-3.
4
Plasminogen activators, tissue degradation, and cancer.纤溶酶原激活剂、组织降解与癌症
Adv Cancer Res. 1985;44:139-266. doi: 10.1016/s0065-230x(08)60028-7.
5
Plasminogen activator inhibitors: hormonally regulated serpins.纤溶酶原激活物抑制剂：受激素调节的丝氨酸蛋白酶抑制剂
Mol Cell Endocrinol. 1990 Jan 2;68(1):1-19. doi: 10.1016/0303-7207(90)90164-4.
Zotero 插件